Lexicon Pharmaceuticals, Inc. – NASDAQ:LXRX

Add to watchlist

$1.14

+0.36

+47.41%

Market open

Closed in about 1 hour

-60.96%

month

-60.96%

quarter

-47.05%

year

Market Cap	248.27M
Enterprise value	410.02M

P/E	-3.78
EV/Sales	2949.80
EV/EBITDA	-4.15
Price/Sales	2885.42
Price/Book	3.42
PEG ratio	1.13
EPS	-0.83

Revenue	2.31M
EBITDA	-181.34M
Income	-192.07M
Revenue Q/Q	4608.33%
Revenue Y/Y	1734.12%

Profit margin	-73341.01%
Oper. margin	-72489.21%
Gross margin	0%
EBIT margin	-72489.21%
EBITDA margin	-7847.21%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Lexicon Pharmaceuticals Stock Forecast

M Q Y

Last Year

Potential upside: 426.26%

Analysts Price target
Financials & Ratios estimates

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX): Profit margin
Jun 2023	317K	-44.90M	-14165.3%
Sep 2023	162K	-50.52M	-31188.27%
Dec 2023	702K	-48.24M	-6872.36%
Mar 2024	1.13M	-48.39M	-4282.92%

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX): Debt to assets
Jun 2023	316724000	130.36M	41.16%
Sep 2023	276479000	136.96M	49.54%
Dec 2023	229429000	136.31M	59.42%
Mar 2024	417219000	128.35M	30.76%

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX): Cash Flow
Jun 2023	-38.11M	-74.60M	188.99M
Sep 2023	-41.61M	-39.32M	-210K
Dec 2023	-50.54M	51.89M	-1K
Mar 2024	-55.13M	-110.22M	239.38M

Lexicon Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Lexicon Pharmaceuticals
Employees

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX): Employee count
Aug 2023	135
Sep 2023	135
Oct 2023	135
Nov 2023	135
Dec 2023	135
Jan 2024	135
Feb 2024	135
Apr 2024	285
May 2024	285
Jun 2024	285
Jul 2024	285

Lexicon Pharmaceuticals
Hedge Funds Holdings Q1 2023

77.07% -22.93%

of LXRX is owned by hedge funds

66 -34

hedge funds hold LXRX stock

112.25M -34.62M

shares is hold by hedge funds

LXRX hedge funds holdings changes

Lexicon Pharmaceuticals
Insider Trading

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX): Insider trades (number of shares)
Period	Buy	Sel
Jun 2023	27867050	0
Aug 2023	6000	0
Sep 2023	10000	0
Oct 2023	1000000	0
Nov 2023	100000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	28 Apr 2024	DEBBANE RAYMOND director director	Common Stock	8,032	N/A	N/A
Option	28 Apr 2024	SWAIN JUDITH L director director	Common Stock	8,032	N/A	N/A
Option	28 Apr 2024	SWAIN JUDITH L director director	Restricted Stock Units	8,032	N/A	N/A
Option	28 Apr 2024	SOBECKI CHRISTOPHER J director director	Common Stock	8,032	N/A	N/A
Option	28 Apr 2024	SOBECKI CHRISTOPHER J director director	Restricted Stock Units	8,032	N/A	N/A
Option	28 Apr 2024	LEFKOWITZ ROBERT J MD director	Common Stock	8,032	N/A	N/A
Option	28 Apr 2024	LEFKOWITZ ROBERT J MD director	Restricted Stock Units	8,032	N/A	N/A
Option	28 Apr 2024	DEBBANE RAYMOND director director	Restricted Stock Units	8,032	N/A	N/A
Option	28 Apr 2024	BARKER SAM L director director	Common Stock	8,032	N/A	N/A
Option	28 Apr 2024	BARKER SAM L director director	Restricted Stock Units	8,032	N/A	N/A

LXRX insider trading transactions

Lexicon Pharmaceuticals
Patents

Status	Patent	Filling date	Issue date
Application	Application USE OF SOTAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AND MODERATE RENAL IMPAIRMENT Filling date: 24 Jul 2020 Issue date: 25 Aug 2022	24 Jul 2020	25 Aug 2022
Application	Application CONTINUOUS PROCESS FOR PREPARING THE CRYSTALLINE FORM II OF SOTAGLIFLOZIN Filling date: 31 Jul 2020 Issue date: 4 Aug 2022	31 Jul 2020	4 Aug 2022
Application	Application PYRAZOLO[1,5]PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE TO TREAT VIRAL INFECTIONS Filling date: 19 Apr 2021 Issue date: 31 Mar 2022	19 Apr 2021	31 Mar 2022
Application	Application COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS Filling date: 19 Apr 2021 Issue date: 24 Feb 2022	19 Apr 2021	24 Feb 2022
Grant	Grant Utility: Antibodies that bind Notum Pectinacetylesterase Filling date: 15 Feb 2019 Issue date: 13 Jul 2021	15 Feb 2019	13 Jul 2021
Grant	Grant Utility: Crystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-m- ethyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyr- an-2-yl)benzyl)phenyl)butanamide and methods of their synthesis Filling date: 23 Sep 2019 Issue date: 6 Apr 2021	23 Sep 2019	6 Apr 2021
Application	Application USE OF SOTAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 1 DIABETES MELLITUS Filling date: 28 Feb 2020 Issue date: 11 Feb 2021	28 Feb 2020	11 Feb 2021
Application	Application COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 Filling date: 17 Feb 2020 Issue date: 11 Feb 2021	17 Feb 2020	11 Feb 2021
Application	Application SOLID DOSAGE FORMS OF (S)-ETHYL 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHEN- YL)-2,2,2-TRIFLUOROETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOATE Filling date: 19 Nov 2019 Issue date: 14 Jan 2021	19 Nov 2019	14 Jan 2021
Application	Application CRYSTALLINE SOLID FORMS OF N-(1-((2-(DIMETHYLAMINO)ETHYL)AMINO)-2-METHYL-1-OXOPROPAN-2-YL)-4-(4-(2-M- ETHYL-5-((2S,3R,4R,5S,6R)-3,4,5-TRIHYDROXY-6-(METHYLTHIO)TETRAHYDRO-2H-PYR- AN-2-YL)BENZYL)PHENYL)BUTANAMIDE AND METHODS OF THEIR SYNTHESIS Filling date: 23 Sep 2019 Issue date: 13 Aug 2020	23 Sep 2019	13 Aug 2020

LXRX patents

Lexicon Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 2 May 2024	Q1 2024 Earnings Call Transcript
Q3 2023 8 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 3 Aug 2023	Q2 2023 Earnings Call Transcript
Q1 2023 2 May 2023	Q1 2023 Earnings Call Transcript

LXRX earnings call transcripts

Lexicon Pharmaceuticals
Executives

Insider	Age	Compensation
Mr. Lonnel Coats (1965) Chief Executive Officer & Director	60	$1,150,000
Mr. Jeffrey L. Wade J.D. (1965) Pres & Chief Financial Officer	60	$655,180
Dr. Alan J. Main Ph.D. (1954) Executive Vice President of Innovation & Chemical Sciences	71	$560,170
Mr. Brian T. Crum (1973) Vice President, Gen. Counsel & Sec.	52	$536,920
Dr. Robert J. Lefkowitz (1944) Consultant & Independent Director	81	$50,000

Lexicon Pharmaceuticals
Latest News

Friday, 20 December 2024
16:46	US FDA declines to approve Lexicon Pharma's add-on diabetes drug	reuters.com
16:30	Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)	globenewswire.com
Tuesday, 26 November 2024
08:00	Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)	globenewswire.com
Monday, 25 November 2024
16:15	Lexicon Pharmaceuticals to Participate in December Investor Conferences	globenewswire.com
Friday, 22 November 2024
07:47	Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development	reuters.com
07:32	Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA	globenewswire.com
Wednesday, 20 November 2024
16:05	Lexicon Appoints Ivan H. Cheung to Board of Directors	globenewswire.com
Tuesday, 12 November 2024
20:39	Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript	seekingalpha.com
18:26	Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates	zacks.com
16:05	Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
Wednesday, 6 November 2024
08:00	Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference	globenewswire.com
Tuesday, 5 November 2024
16:05	Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease	globenewswire.com
Thursday, 31 October 2024
18:54	Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease	globenewswire.com
16:54	FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes	reuters.com
Wednesday, 16 October 2024
16:35	Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe	globenewswire.com
16:34	Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe	prnewswire.com
Friday, 27 September 2024
08:00	Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress	globenewswire.com
Monday, 16 September 2024
08:00	Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer	globenewswire.com
Tuesday, 10 September 2024
08:00	New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes	globenewswire.com
Tuesday, 3 September 2024
16:00	Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences	globenewswire.com
Thursday, 22 August 2024
12:30	Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista	zacks.com
Wednesday, 14 August 2024
13:35	Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up	zacks.com
Tuesday, 13 August 2024
08:30	Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio	globenewswire.com
Wednesday, 7 August 2024
08:00	Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists	globenewswire.com
Saturday, 3 August 2024
06:29	Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success	seekingalpha.com
Thursday, 1 August 2024
23:00	Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2024 Earnings Call Transcript	seekingalpha.com
18:15	Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates	zacks.com
Tuesday, 30 July 2024
08:49	5 Penny Stocks With 250% Upside in 1 Year According to Wall Street	247wallst.com
Thursday, 25 July 2024
08:00	Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024	globenewswire.com
Wednesday, 17 July 2024
12:17	FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug	zacks.com

Ideas & Opinions

Seeking Alpha 29 Apr 2025

Growth Is Priced Out Of Novo Nordisk
Seeking Alpha 26 Jan 2024

Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do
Seeking Alpha 4 Jan 2024

Lexicon Pharma: Inpefa's Early Clinical Benefits, Rehospitalization Data May Unlock Significant Value
Seeking Alpha 25 Dec 2022

Nothing Ever Comes Easy For Lexicon, But Maybe Sotagliflozin Will Prevail In Heart Failure
Seeking Alpha 31 May 2022

Lexicon: Beaten Down Stock, High Risk-Reward Situation Ahead
Seeking Alpha 27 May 2021

Lexicon Pharmaceuticals Still A Very High-Risk/High-Reward Biopharma Name

Frequently Asked Questions (FAQ)

What's the price of Lexicon Pharmaceuticals stock today?

One share of Lexicon Pharmaceuticals stock can currently be purchased for approximately $1.14.
When is Lexicon Pharmaceuticals's next earnings date?

Unfortunately, Lexicon Pharmaceuticals's (LXRX) next earnings date is currently unknown.
Does Lexicon Pharmaceuticals pay dividends?

No, Lexicon Pharmaceuticals does not pay dividends.
How much money does Lexicon Pharmaceuticals make?

Lexicon Pharmaceuticals has a market capitalization of 248.27M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 766.19% to 1.2M US dollars.
What is Lexicon Pharmaceuticals's stock symbol?

Lexicon Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "LXRX".
What is Lexicon Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Lexicon Pharmaceuticals?

Shares of Lexicon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Lexicon Pharmaceuticals's key executives?
Lexicon Pharmaceuticals's management team includes the following people:
- Mr. Lonnel Coats Chief Executive Officer & Director(age: 60, pay: $1,150,000)
- Mr. Jeffrey L. Wade J.D. Pres & Chief Financial Officer(age: 60, pay: $655,180)
- Dr. Alan J. Main Ph.D. Executive Vice President of Innovation & Chemical Sciences(age: 71, pay: $560,170)
- Mr. Brian T. Crum Vice President, Gen. Counsel & Sec.(age: 52, pay: $536,920)
- Dr. Robert J. Lefkowitz Consultant & Independent Director(age: 81, pay: $50,000)
How many employees does Lexicon Pharmaceuticals have?

As Jul 2024, Lexicon Pharmaceuticals employs 285 workers.
When Lexicon Pharmaceuticals went public?

Lexicon Pharmaceuticals, Inc. is publicly traded company for more then 25 years since IPO on 7 Apr 2000.
What is Lexicon Pharmaceuticals's official website?

The official website for Lexicon Pharmaceuticals is lexpharma.com.
Where are Lexicon Pharmaceuticals's headquarters?

Lexicon Pharmaceuticals is headquartered at 2445 Technology Forest Boulevard, The Woodlands, TX.
How can i contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals's mailing address is 2445 Technology Forest Boulevard, The Woodlands, TX and company can be reached via phone at 281 863 3000.
What is Lexicon Pharmaceuticals stock forecast & price target?

Based on 1 Wall Street analysts` predicted price targets for Lexicon Pharmaceuticals in the last 12 months, the avarage price target is $6. The average price target represents a 426.26% change from the last price of $1.14.

Lexicon Pharmaceuticals, Inc.

lexpharma.com

Exchange:

NASDAQ

Full time employees:

285

Industry:

Biotechnology

Sector:

Healthcare

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

281 863 3000

2445 Technology Forest Boulevard
The Woodlands, TX 77381

CIK: 0001062822
ISIN: US5288723027
CUSIP: 528872302